Implementer & leader of a new business process management capability for Clinical Operations to support strategic & tactical business process innovation & improvement initiatives. Performed process analytics & consulting assignments to test change scenarios, identifying operating deviations and delivery of lean solutions to establish clinical operation efficiencies. Provided leadership, strategic direction and implemented a 'best in class' Business Process Management System (BPMS), to build a digital infrastructure and embedded governance for GSK processes.Used agile methodologies to develop innovative solutions to unlock operational potential, enable access to process intelligence (Risk, CAPAs, Findings, documents, people, systems) and promote information exchange.Created a business process framework, and via process intelligence identified, aligned and analyzed risks associated to business activity and ensured the embedment of internal quality control steps to aid continuous and pre-emptive risk assessments.Performed end-to-end process modelling and conducted in-depth reviews of cross functional ‘as is’ processes with SMEs to aid process integration, Leader of process modelling workshops to systematically tackling complexity (simplify) and reducing variability (standardize). Established a WS governance model for planning, creating and tracking the periodic review of written standards to ensure that mandatory steps, accountabilities & quality control points are described in enough detail to reflect GCP and Clinical Trial Regulations.Collaborated with Process Owners/ Business Leads to ensure process and procedural document cohesion and reduce duplication & diversification across GSK’s document landscape. Monitored BPM trends both internal and external, and applied learnings to process development to enable data driven decision making & optimize solution generation. Line Manager of Business Process Information Architects.

Clinical Operations Development lead for Phase II-III clinical trials in Immune Mediated Disease. Ensured maximum commercial value and ensure consistency with the overall product and therapy area strategy. Represented Clinical Operations within Business Development workstreams; Conducted SOPs reviews, streamlined R&D and corporate policies. Cost center owner for the Global RA development program budget.

Manager of a novel compound for Overactive Bladder (OAB) and Clinical Operational Development lead for Psoriasis Programme. Primary European Clinical contact for OAB in-licensing activities; Established an OAB portfolio and lead the creation of its regional clinical development strategy plan and oversaw its implementation.

Global Study Team leader for a Phase III pivotal efficacy study in Benign Prostatic Hyperplasia (BPH) from study design to submission/file

European Study manager, for a multinational phase III clinical trial in Chronic Hepatitis C. Authored country specific amendments, and responsible for study set-up & delivery in Europe, Coached & Trained new CRA's in process.

U.K. co-ordinator for a multinational phase III clinical trial in Benign Prostatic Obstruction and phase II/III studies in Acute Ischaemic Stroke.

UK CRA responsible for the Monitoring of Phase III/IV trials in the area of Hypertension, Osteoporosis, HIV and Bone Marrow Disease.